Oslo, Norway, 7 May, 2025 - EXACT Therapeutics AS (Euronext Growth: EXTX), a
clinical stage precision medicine company utilizing the power of ultrasound to
enable targeted drug delivery in oncology, has been informed that the
Intellectual Property Office in Japan has granted EXACT its patent no. 7662207
entitled "Treatment of pancreatic cancer".
The granted patent covers the treatment of pancreatic cancer using EXACT's
proprietary Acoustic Cluster Therapy (ACT®).
Per Walday, CEO of EXACT Therapeutics, comments, "We are delighted to announce
the granting of this key patent in Japan, giving us patent protection within
pancreatic cancer until 2040. As one of the major markets outside U.S. and
Europe, Japan represents a significant part of the attractive commercial
opportunity for the ACT® technology. EXACT has initiated its Phase 2 ENACT trial
in pancreatic cancer and remains on track to commence recruitment in the near
term."
About Exact Therapeutics
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications, including brain diseases. EXACT has an on-going
Phase 2 trial for the treatment of locally advanced pancreatic cancer. EXACT
Therapeutics' shares are traded on Euronext Growth Oslo (EXTX).
www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com